Intra-cellular Therapies Inc (NASDAQ:ITCI) Has Decline in Shorts

Investors sentiment increased to 1.4 in 2019 Q2. Its up 0.07, from 1.33 in 2019Q1. It increased, as 15 investors sold Intra-Cellular Therapies, Inc. shares while 25 reduced holdings. 13 funds opened positions while 43 raised stakes. 34.58 million shares or 6.28% less from 36.90 million shares in 2019Q1 were reported.
Blume Capital Incorporated has 1,000 shares for 0.01% of their portfolio. Macquarie Gp Limited accumulated 107,616 shares or 0% of the stock. Gemmer Asset Mgmt Ltd Limited Liability Company holds 10,000 shares. Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 6,019 shares. Millennium Mngmt Limited Liability has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Panagora Asset Mngmt invested in 44,569 shares or 0% of the stock. Morgan Stanley holds 461,669 shares or 0% of its portfolio. Invesco Limited holds 33,761 shares or 0% of its portfolio. Legal General Group Inc Public Limited Co owns 0% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 16,044 shares. Bank Of Ny Mellon Corporation holds 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 205,423 shares. Price T Rowe Associates Md invested in 0% or 355,500 shares. Clear Street Markets Ltd Com has 0.07% invested in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) for 45,735 shares. Northern Trust Corp invested in 560,601 shares. Jefferies Gru Llc invested 0% of its portfolio in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Art Advsr has 33,221 shares.

Since May 14, 2019, it had 4 insider buys, and 0 sales for $9.29 million activity.

The stock of Intra-cellular Therapies Inc (NASDAQ:ITCI) registered a decrease of 0.1% in short interest. ITCI’s total short interest was 4.68 million shares in September as published by FINRA. Its down 0.1% from 4.68 million shares, reported previously. With 643,400 shares average volume, it will take short sellers 7 days to cover their ITCI’s short positions.

The stock decreased 4.97% or $0.52 during the last trading session, reaching $9.94. About 1.08M shares traded. Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has declined 57.38% since September 13, 2018 and is downtrending. It has underperformed by 57.38% the S&P500.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease. The company has market cap of $548.42 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders. It currently has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Among 2 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Intra-Cellular Therapies has $2100 highest and $1600 lowest target. $18.50’s average target is 86.12% above currents $9.94 stock price. Intra-Cellular Therapies had 3 analyst reports since May 16, 2019 according to SRatingsIntel. The rating was maintained by JMP Securities on Thursday, August 8 with “Market Outperform”.

More notable recent Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news were published by: which released: “7 Stocks on Sale the Insiders Are Buying – Nasdaq” on June 27, 2019, also with their article: “Microcaps mostly among midday movers – Seeking Alpha” published on July 08, 2019, published: “Intra-Cellular Therapies: Poised To Rally – Seeking Alpha” on July 19, 2019. More interesting news about Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) were released by: and their article: “Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology – GlobeNewswire” published on December 11, 2018 as well as‘s news article titled: “Mid-Morning Market Update: Markets Open Lower; HD Supply Posts Mixed Q2 Results – Benzinga” with publication date: September 10, 2019.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.